DOI:
10.1055/s-00034914
Osteologie
LinksClose Window
References
Crawford J, Prado CMM, Johnston MA. et al.
Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials).
Curr Oncol Rep 2016
18.
Access:
We do not assume any responsibility for the contents of the web pages of other providers.